GNH USA

Europe — EMA

Nemluvio (Nemolizumab)

GNH USA supplies Nemluvio (Nemolizumab), a monoclonal antibody for atopic dermatitis and associated pruritus. Request a quote for global supply.

Nemolizumab

Request sourcing

1
Pack/s

What is Nemolizumab?

Nemolizumab, the active ingredient in Nemluvio, is a monoclonal antibody presented as a sterile solution for subcutaneous use. It is indicated for the treatment of atopic dermatitis and the associated pruritus in patients who require systemic therapy.

GNH USA supplies Nemluvio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Nemolizumab used for?

Nemluvio targets the IL‑31 pathway, a key driver of itch and inflammation in dermatologic disease.

Atopic dermatitis: reduces skin inflammation and relieves itch. Pruritus associated with atopic dermatitis: diminishes severity of itch episodes. Eczema (atopic dermatitis): improves lesion appearance and patient quality of life.

What are the side effects of Nemolizumab?

Adverse reactions may occur with subcutaneous administration of Nemluvio.

Common Side Effects: - Injection site erythema or pain. - Nasopharyngitis. - Headache. - Upper respiratory tract infection. - Dry mouth. - Fatigue.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Severe infection requiring hospitalization. - Cytopenias (e.g., neutropenia, thrombocytopenia). - Autoimmune phenomena. - Cardiovascular events (e.g., myocardial infarction).

What precautions apply to Nemolizumab?

Clinicians should consider several safety aspects before prescribing Nemluvio.

Pregnancy: safety not established; avoid unless benefit outweighs risk. Breastfeeding: unknown excretion; caution advised. Infection risk: monitor for signs of serious infection. Immunogenicity: potential development of anti‑drug antibodies. Concomitant immunosuppressants: assess cumulative immunosuppression. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Nemolizumab interact with?

Nemluvio may interact with other agents that affect immune function.

Major Interactions (Avoid): - Live vaccines: contraindicated during therapy. - Concurrent IL‑31 pathway inhibitors: risk of additive immunosuppression.

Moderate Interactions (Monitor Closely): - Other immunosuppressive drugs (e.g., methotrexate, cyclosporine): monitor infection risk. - Anticoagulants: watch for bleeding if injection site reactions occur. - CYP450 substrates: no direct effect, but monitor clinical response. - Herbal immunomodulators (e.g., echinacea): assess for enhanced immune alteration.

Frequently asked questions

What conditions is Nemluvio used to treat?+
Nemluvio is prescribed for patients with atopic dermatitis and for the relief of pruritus that accompanies this skin condition. It helps reduce inflammation and the intense itching that characterises the disease.
How does Nemolizumab work in the body?+
Nemolizumab is a monoclonal antibody that binds to the interleukin‑31 receptor A (IL‑31RA). By blocking IL‑31 signaling, it interrupts the pathway that triggers itch and inflammatory responses in the skin, leading to symptom improvement.
What is the usual dose of Nemluvio?+
The dosing regimen for Nemluvio is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. Specific dose amounts and intervals are individualized and should follow the prescriber’s instructions.
Is Nemluvio safe to use during pregnancy or breastfeeding?+
Safety data for Nemluvio in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.
How do I order Nemluvio from GNH USA?+
To request Nemluvio, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.
How does Nemluvio compare with other treatments for atopic dermatitis?+
Nemluvio targets the IL‑31 pathway, whereas many traditional systemic agents (e.g., cyclosporine, methotrexate) act more broadly on immune suppression. Compared with other biologics such as dupilumab, Nemluvio focuses specifically on itch reduction, offering a complementary mechanism for patients who need additional pruritus control.
What are the storage requirements for Nemluvio?+
Nemluvio must be stored in a refrigerated environment between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken to maintain product integrity.
How is Nemluvio administered?+
Nemluvio is given as a subcutaneous injection. The injection is performed by a qualified healthcare professional, typically in a clinical setting, following the dosing schedule prescribed by the treating physician.
What are the most serious risks associated with Nemluvio?+
Serious risks include severe hypersensitivity reactions such as anaphylaxis, serious infections that may require hospitalization, and rare hematologic abnormalities like neutropenia or thrombocytopenia. Patients should be monitored closely for any signs of these events.
Who should not use Nemluvio?+
Nemluvio is contraindicated in individuals with known hypersensitivity to nemolizumab or any of its excipients. Patients receiving live vaccines, or those with uncontrolled severe infections, should also avoid this therapy until the underlying issue is resolved.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Nemolizumab
Route
Subcutaneous Use
Manufacturer
Galderma International
Origin
EU

Related products

Nemluvio

Nemluvio

Nemolizumab

Galderma International
EU
Nemluvio

Nemluvio

Nemolizumab

Galderma International
EU
Nemluvio

Nemluvio

Nemolizumab

Galderma International
EU